Vaninetti NM, et al. - This retrospective analysis compared sellar masses that could be present either with clinical manifestations of mass effect/hormonal dysfunction (CMSM) or incidentally on imaging (PI). No notable variations were detected in the risk of new-onset secondary hormone deficiencies (SHD) in CMSM vs PI in those who underwent surgery and those were followed without surgery. Yielded data underscored the need for comprehensive baseline and long-term radiological and hormonal evaluations in both entities.

Methods

• All patients within a provincial pituitary registry were examined between January 2006 and June 2014 in this retrospective analysis.

Results

• The enrollment consisted of 903 patients (681 CMSM, 222 PI).
• It was reported that CMSM primarily presented with secondary hormone deficiencies (SHD) or stalk compression (29.7%).
• On the other hand, PI were detected in association with neurological complaints (34.2%) (p < 0.0001).
• PI exhibited a greater tendency of being macroadenomas (70.7% vs 49.9%; p < 0.0001).
• The commonest pathologies among CMSM were discovered to be prolactinomas (39.8%) and nonfunctioning adenomas (NFA) (50%) in PI (p < 0.0001).
• As per the data, SHD were present in 41.3% CMSM and 31.1% PI patients (p < 0.0001) and visual field deficit in 24.2% and 29.3%, respectively (p=0.16).
• CMSM illustrated a greater likelihood of requiring surgery (62.9%) compared to PI (35.8%) (p < 0.0005).
• Findings reported that impaired vision and radiological evidence of optic nerve compression were the commonest surgical indications.
• The occurrence of tumour growth/recurrence was noted in 7.8% of surgically treated CMSM and 2.6% without surgery over a follow-up period of 5.7 years for CMSM and 5.0 years for PI, as well as PI, 0% and 4.9%, respectively (p=1.0).
• No marked variations were displayed in the risk of new-onset SHD in CMSM vs PI in those who underwent surgery (p=0.7) and those were followed without surgery (p=0.58).